Rix, U.Colinge, J.Blatt, K.Gridling, M.Remsing Rix, L.Parapatics, K.Cerny-Reiterer, S.Burkard, T.Jäger, U.Melo, J.Bennett, K.Valent, P.Superti-Furga, G.Bendall, L.2015-08-072015-08-072013PLoS ONE, 2013; 8(10):e77155-1-e77155-141932-62031932-6203http://hdl.handle.net/2440/93363Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is in part driven by the tyrosine kinase bcr-abl, but imatinib does not produce long-term remission. Therefore, second-generation ABL inhibitors are currently in clinical investigation. Considering different target specificities and the pronounced genetic heterogeneity of Ph+ ALL, which contributes to the aggressiveness of the disease, drug candidates should be evaluated with regard to their effects on the entire Ph+ ALL-specific signaling network. Here, we applied an integrated experimental and computational approach that allowed us to estimate the differential impact of the bcr-abl inhibitors nilotinib, dasatinib, Bosutinib and Bafetinib. First, we determined drug-protein interactions in Ph+ ALL cell lines by chemical proteomics. We then mapped those interactions along with known genetic lesions onto public protein-protein interactions. Computation of global scores through correlation of target affinity, network topology, and distance to disease-relevant nodes assigned the highest impact to dasatinib, which was subsequently confirmed by proliferation assays. In future, combination of patient-specific genomic information with detailed drug target knowledge and network-based computational analysis should allow for an accurate and individualized prediction of therapy.en© 2013 Rix et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.Molecular Targeted TherapyJournal article003002741110.1371/journal.pone.00771550003258142000622-s2.0-84885398764183941Melo, J. [0009-0009-5343-4893]